PALVELLA THERAPEUTICS, INC.
corporate_fare Company Profile
PALVELLA THERAPEUTICS, INC. (NASDAQ:PVLA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for PVLA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-31, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PVLA spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Palvella Completes NDA Submission for QTORIN Rapamycin, Eyes 2027 Launch
- Palvella Q2 2026: $250.6M Cash, NDA Rolling Review Underway, Pipeline Advances
- Palvella Reports Q2 2026 Results: $250.6M Cash, NDA Submission Underway, Pipeline Advances
- Palvella Therapeutics Posts Wider Q2 Loss of $1.52/Shr
- Palvella's July 2026 Corporate Presentation: NDA Submission Underway, Launch Planning Ramps Up, Pipeline Broadens
Financial Snapshot
Short Interest & Short Volume
12.82 days to coverFINRA reported short interest of 2,325,699 shares in PVLA as of the September 15, 2026 settlement, a 1.5% increase from the prior period — about 12.8 days to cover at its recent average daily volume. On October 8, 2026, 88.5% of PVLA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.